- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04595747
Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST)
Phase 2 Study of Rogaratinib (BAY 1163877) in the Treatment of Patients With Sarcoma Harboring Alterations in Fibroblast Growth Factor Receptor (FGFR) 1-4 and SDH-Deficient Gastrointestinal Stromal Tumor (GIST)
Study Overview
Status
Conditions
- Metastatic Gastrointestinal Stromal Tumor
- Metastatic Sarcoma
- Locally Advanced Sarcoma
- Locally Advanced Gastrointestinal Stromal Tumor
- Stage III Gastric and Omental Gastrointestinal Stromal Tumor AJCC v8
- Stage III Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor AJCC v8
- Stage IV Gastric and Omental Gastrointestinal Stromal Tumor AJCC v8
- Stage IV Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor AJCC v8
Detailed Description
PRIMARY OBJECTIVE:
I. To estimate the objective radiographic response rate to single agent rogaratinib (BAY 1163877) in two cohorts of patients with sarcoma: Cohort A defined as patients with a sarcoma which harbors an alteration in fibroblast growth factor receptor (FGFR) 1, 2, 3 or 4 identified by next-generation sequencing profiling, and Cohort B defined as patients with advanced succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumor (GIST).
SECONDARY OBJECTIVES:
I. To estimate progression-free survival (PFS) in patients in Cohort A and Cohort B treated with rogaratinib (BAY 1163877).
II. Further assessment for safety and tolerability.
EXPLORATORY OBJECTIVES:
I. To evaluate serial measurements of FGFR and FGFR ligand in serial tumor biopsies as potential pharmacodynamic markers of FGFR pathway inhibition by ribonucleic acid sequencing (RNA-seq) (pre-treatment biopsy and post-progression biopsy [if available]).
II. Whole exome sequencing (WES) of the pre-treatment biopsy and post-progression biopsy (if available) to help identify mechanisms of resistance.
III. To bank tumor material, germline deoxyribonucleic acid (DNA), and peripheral blood for potential future research for participating subjects who provide additional consent.
IV. To explore rogaratinib exposure with pharmacodynamics effects (i.e., clinical response, toxicity, and markers of FGFR pathway inhibition).
OUTLINE:
Patients receive rogaratinib orally (PO) twice daily (BID) on days 1-28 of each cycle. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo biopsy at baseline and progression and computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET)-CT every 8 weeks. Patients may also undergo blood sample collection on study.
After completion of study treatment, patients are followed up at 30 days.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Duarte, California, United States, 91010
- City of Hope Comprehensive Cancer Center
-
Irvine, California, United States, 92618
- City of Hope At Irvine Lennar
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- UCHealth University of Colorado Hospital
-
-
Florida
-
Miami, Florida, United States, 33136
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
Plantation, Florida, United States, 33324
- UM Sylvester Comprehensive Cancer Center at Plantation
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Northwestern University
-
-
Maryland
-
Bethesda, Maryland, United States, 20892
- National Institutes of Health Clinical Center
-
Bethesda, Maryland, United States, 20892
- National Cancer Institute Developmental Therapeutics Clinic
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Dana-Farber Cancer Institute
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- University of Michigan Comprehensive Cancer Center
-
-
Missouri
-
Creve Coeur, Missouri, United States, 63141
- Siteman Cancer Center at West County Hospital
-
Saint Louis, Missouri, United States, 63110
- Washington University School of Medicine
-
Saint Louis, Missouri, United States, 63129
- Siteman Cancer Center-South County
-
-
New York
-
New York, New York, United States, 10065
- Memorial Sloan Kettering Cancer Center
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- Ohio State University Comprehensive Cancer Center
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15232
- University of Pittsburgh Cancer Institute (UPCI)
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232
- Vanderbilt University/Ingram Cancer Center
-
-
Texas
-
Houston, Texas, United States, 77030
- M D Anderson Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Participant must have histologically confirmed sarcoma with FGFR alteration identified by next-generation sequencing profiling with the exception of SDH-deficient GIST who can be enrolled regardless of FGFR status. Initial testing can be performed on archival tissue. Patients must have locally advanced or metastatic disease that is not amenable to surgery
- Presence of measurable disease: Patient must have measurable disease
- Patients must have progressed following at least one standard prior chemotherapy regimen with the exception of SDH-deficient GIST for which there is no standard of care
- Participant must be willing to undergo pre-treatment biopsy if disease site is amenable to biopsy and low risk for the biopsy procedure. If biopsy is not possible, eligibility may be approved after discussion with the Study Chair. Of note, a minimum of 15 participants in each arm open to stage 2 should have disease amenable to biopsy. For those arms open in stage 1, all patients should have biopsiable disease.
Age >= 18 years
- Because no dosing or adverse event data are currently available on the use of rogaratinib (BAY 1163877) in patients <18 years of age, children are excluded from this study
- Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)
- Hemoglobin >= 8.0 g/dL
- Absolute neutrophil count >= 1,000/mcL
- Platelets >= 100,000/mcL
- Total bilirubin =< 1.5 x institutional upper limit of normal (ULN)
- Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 3.0 x institutional ULN (unless liver metastases are present in which case it must be =< 5 x ULN)
- Glomerular filtration rate (GFR) >= 60 mL/min/1.73 m^2 (using the Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] formula)
- Human immunodeficiency virus (HIV)-infected patients on effective non-CYP3A4 interacting anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
- For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
- Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
- Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression
Patients must be disease-free of prior invasive malignancies for > 5 years with the exception of curatively-treated basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix
- NOTE: If there is a history of prior malignancy, patients must not be receiving other specific treatment for that cancer
- Patients should have completed prior treatment for their cancer: chemotherapy or radiotherapy must have been completed for greater than 2 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study
- Patients should have recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > grade 1) with the exception of alopecia
- Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association functional classification. To be eligible for this trial, patients should be class 2B or better
- Patients must have a QTc interval length of below 450 millisecond (msec)
- Participant is willing to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up
- Participant must be able to swallow and maintain pills
- Women of childbearing potential must have a negative urine or serum pregnancy test within 28 days of initial dose of rogaratinib (BAY 1163877), and again within 7 days prior to treatment on day 1. If screening occurs within 7 days of day 1, only one pregnancy test is required
- The effects of rogaratinib (BAY 1163877) on the developing human fetus are unknown. For this reason and because kinase inhibitor agents are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and 4 months after completion of rogaratinib (BAY 1163877). Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of rogaratinib (BAY 1163877) administration
- Ability to understand and the willingness to sign a written informed consent document. Participants with impaired decision-making capacity (IDMC) who have a legally-authorized representative (LAR) and/or family member available will also be eligible
Exclusion Criteria:
- Patients who are receiving any other investigational agents
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to rogaratinib (BAY 1163877)
- Concomitant administration with sensitive substrates/narrow therapeutic index drugs of CYP3A4, P-gp BCRP, MATE1, and MATE2K, and strong inhibitors and inducers of CYP3A4 should be avoided. Use caution with strong inhibitors and inducers of P-glycoprotein (gp). Because the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated medical reference. As part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product
- Concomitant administration of medications that prolong QT/QTc interval is prohibited in accordance with the published FDA guidance "E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs".
- Patients with disturbed calcium and/or phosphate metabolism are excluded from this study
- Patients with uncontrolled intercurrent illness
- Patients with psychiatric illness/social situations that would limit compliance with study requirements
- Pregnant women are excluded from this study because rogaratinib (BAY 1163877) is kinase inhibitor agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with rogaratinib (BAY 1163877), breastfeeding should be discontinued if the mother is treated with rogaratinib (BAY 1163877)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment (rogaratinib)
Patients receive rogaratinib PO BID on days 1-28 of each cycle.
Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
Patients undergo biopsy at baseline and progression and CT, MRI, and PET-CT every 8 weeks.
Patients may also undergo blood sample collection on study.
|
Undergo MRI
Other Names:
Undergo blood sample collection
Other Names:
Undergo PET/CT scan
Other Names:
Undergo biopsy
Other Names:
Undergo CT scan and PET/CT scan
Other Names:
Given PO
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective radiographic response
Time Frame: Up to 30 days after removal from study
|
The duration of overall response is measured from the time measurement criteria are met for complete response or partial response (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented (taking as reference for progressive disease the smallest measurements recorded since the treatment started).
|
Up to 30 days after removal from study
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free survival
Time Frame: From start of treatment to time of progression or death, whichever occurs first, assessed up to 30 days after removal from study
|
Will be estimated using Kaplan-Meier method.
|
From start of treatment to time of progression or death, whichever occurs first, assessed up to 30 days after removal from study
|
Incidence of adverse events
Time Frame: Up to 30 days after removal from study
|
Adverse events will be measured by the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0.
|
Up to 30 days after removal from study
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Serial measurements of FGFR and FGFR ligand
Time Frame: Up to 30 days after removal from study
|
Will be evaluated in serial tumor biopsies as potential pharmacodynamic markers of FGFR pathway inhibition by ribonucleic acid sequencing.
Estimation of continuous biomarker measures will be via mean or median as appropriate and standard deviation.
|
Up to 30 days after removal from study
|
Mechanisms of resistance
Time Frame: Up to 30 days after removal from study
|
Will identify mechanisms of resistance via whole exome sequencing of pre- and post-treatment biopsies and considered exploratory.
|
Up to 30 days after removal from study
|
Banking of tumor material, germline deoxyribonucleic acid, and peripheral blood
Time Frame: Up to 30 days after removal from study
|
Will be banked for potential research.
|
Up to 30 days after removal from study
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Suzanne George, Dana-Farber - Harvard Cancer Center LAO
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NCI-2020-08011 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- UM1CA186709 (U.S. NIH Grant/Contract)
- 21-070
- 10411 (Other Identifier: Fred Hutch/University of Washington Cancer Consortium)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Gastrointestinal Stromal Tumor
-
Centre Leon BerardRecruitingMetastatic Gastrointestinal Stromal Tumor | Unresectable Gastrointestinal Stromal Tumor (GIST) | Locally Advanced Gastrointestinal Stromal Tumor (GIST)France
-
Hospital Universitario Virgen de la ArrixacaNot yet recruitingLiver Diseases | Liver Transplantation | Liver Neoplasms | Gastrointestinal Stromal Tumors | Metastasis | Liver Metastases | Liver Transplant; Complications | Liver Cancer | Liver Transplant Disorder | Liver Carcinoma | GIST, Malignant | GIST | Metastases | Metastatic Liver Cancer | Gastrointestinal Stromal Tumor of... and other conditionsSpain
-
Centre Leon BerardRecruitingC-KIT Mutation | Metastatic Gastrointestinal Stromal Tumor (GIST) | Advanced Gastrointestinal Stromal Tumor (GIST)France
-
European Organisation for Research and Treatment...CompletedMetastatic Gastrointestinal Stromal TumorFrance, United Kingdom, Belgium, Czechia, Germany, Hungary
-
Novartis PharmaceuticalsCompletedUnresectable or Metastatic Malignant Gastrointestinal Stromal Tumor (GIST)United States, Finland, Australia
-
Assaf-Harofeh Medical CenterUnknownSoft Tissue Sarcoma | Osteosarcoma | Chondrosarcoma | Bone Sarcoma | Desmoplastic Small Round Cell Tumor | Gastrointestinal Stromal Sarcoma | Ewing's Tumor Metastatic | Ewing's Tumor Recurrent
-
IDRx, Inc.RecruitingGastrointestinal Diseases | Metastatic Cancer | Digestive System Disease | Gastrointestinal Stromal Tumor (GIST)United States, Belgium, Germany, Spain
-
Translational Research Center for Medical Innovation...Niigata University Medical & Dental HospitalCompletedMetastatic Cancer | Gastrointestinal Stromal TumorJapan
-
Translational Research Center for Medical Innovation...Niigata University Medical & Dental HospitalCompletedMetastatic Cancer | Gastrointestinal Stromal TumorJapan
-
Ascentage Pharma Group Inc.HealthQuest Pharma Inc.RecruitingSolid Tumor, Adult | Gastrointestinal Stromal Tumor (GIST)China
Clinical Trials on Magnetic Resonance Imaging
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Recruiting
-
University of California, San FranciscoTerminatedAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
University of MichiganPhilips Healthcare; General ElectricCompleted
-
American College of Radiology Imaging NetworkNational Cancer Institute (NCI)Completed
-
M.D. Anderson Cancer CenterActive, not recruitingProstate Adenocarcinoma | Prostate CarcinomaUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Healthy SubjectUnited States
-
Stanford UniversityTerminatedLaryngeal Neoplasms | Head and Neck Cancers | Larynx CancerUnited States
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI)CompletedBreast CancerUnited States
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityRecruitingIntracranial NeoplasmUnited States